The Goldman Sachs Group Issues Pessimistic Forecast for Esperion Therapeutics (NASDAQ:ESPR) Stock Price

Esperion Therapeutics (NASDAQ:ESPR) had its target price reduced by equities researchers at The Goldman Sachs Group from $4.00 to $3.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price would indicate a potential upside of 215.79% from the stock’s previous close.

ESPR has been the topic of several other reports. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, April 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Esperion Therapeutics presently has an average rating of “Hold” and an average target price of $6.42.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $0.95 on Thursday. Esperion Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $3.94. The company has a market cap of $187.96 million, a PE ratio of -1.48 and a beta of 0.86. The business’s 50-day simple moving average is $1.49 and its two-hundred day simple moving average is $1.99.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently made changes to their positions in the stock. Cibc World Markets Corp acquired a new stake in Esperion Therapeutics in the 4th quarter valued at approximately $39,000. SJS Investment Consulting Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $55,000. Crestline Management LP purchased a new stake in shares of Esperion Therapeutics in the 4th quarter valued at $63,000. Foundations Investment Advisors LLC lifted its stake in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 9,872 shares in the last quarter. Finally, J.W. Cole Advisors Inc. purchased a new position in Esperion Therapeutics during the 4th quarter valued at about $66,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.